Bioxytran Secures $1.2M Private Placement at Premium to Market, Issues Warrants

summarizeSummary

Bioxytran, Inc. completed a private placement, raising $1.2 million by issuing common stock at a premium to its current market price and also issued warrants, strengthening its balance sheet for working capital and development.

check_boxKey Events

• $1.2 Million Private Placement Completed

  The company completed a private placement on March 18, 2026, raising approximately $1.2 million in gross proceeds from accredited investors.

• Equity and Warrant Issuance

  An aggregate of 21,071,667 shares of common stock were issued at approximately $0.055 per share. Additionally, warrants to purchase up to 19,750,001 shares of common stock were issued, exercisable at $0.12 per share for five years.

• Offering Priced at a Premium

  The common stock was issued at a purchase price of $0.055 per share, which is a premium compared to the current market price of $0.0362 per share.

• Use of Proceeds

  The net proceeds from the offering are intended for working capital and general corporate purposes, including advancing development programs and supporting commercialization initiatives.

auto_awesomeAnalysis

This significant capital raise of $1.2 million is crucial for Bioxytran, a micro-cap company, as it provides essential working capital and supports its development and commercialization initiatives. While the issuance of over 21 million shares and warrants for nearly 20 million more represents substantial potential dilution, the fact that the shares were sold at $0.055, a premium to the current market price of $0.0362, indicates strong investor confidence in the company's future prospects. This financing strengthens the balance sheet and extends the operational runway, which is a critical positive for a company at this stage.